The aim of the present study was to investigate whether the MAPK pathways were involved in the mechanism of neuropathic pain in rats with chronic compression of the dorsal root ganglion. We determined the paw withdrawal mechanical threshold (PWMT) of rats before and after CCD surgery and then after p38, JNK, or ERK inhibitors administration. Western blotting, RT-PCR, and immunofluorescence of dorsal root ganglia were performed to investigate the protein and mRNA level of MAPKs and also the alternation in distributions of positive neurons in dorsal root ganglia. Intrathecal administration of MAPKs inhibitors, SB203580 (p38 inhibitor), SP600125 (JNK inhibitor), and U0126 (ERK inhibitor), resulted in a partial reduction in CCD-induced mechanical allodynia. The reduction of allodynia was associated with significant depression in the level of both MAPKs mRNA and protein expression in CCD rats and also associated with the decreased ratios of large size MAPKs positive neurons in dorsal root ganglia. In conclusion, the specific inhibitors of MAPKs contributed to the attenuation of mechanical allodynia in CCD rats and the large size MAPKs positive neurons in dorsal root ganglia were crucial.

1. Introduction

Neuropathic pain caused by lesion or inflammation results from the dysfunction and derangement in transmission and signal processing within the nervous system. It is characterized by the symptoms of allodynia, hyperalgesia, and spontaneous pain [1, 2] and it does not depend on the continued presence of tissue-damaging stimuli and is recognized as a disease in itself [3]. Chronic compression of the dorsal root ganglia (CCD) in rats is a typical model of neuropathic pain. During the formation and development of neuropathic pain, inflammation is inevitable. Pain and hyperalgesia that are produced by tissue damage or infection are common features of the inflammatory process [4]. Evidence demonstrates that a substantial proportion of mediators are involved in the symptoms of neuropathic pain, including cytokines, bradykinin, ATP and adenosine, serotonin, eicosanoids, and neurotrophins [1]. Kinds of drugs are used to alleviate neuropathic pain, but they exhibit limited efficacy and undesirable side effects, and neuropathic pain responds poorly to such drug treatments [5].

Mitogen-activated protein kinases (MAPKs), including p38 mitogen-activated protein kinase (p38), c-Jun N-terminal kinase (JNK), and extracellular-regulated kinase (ERK), are a family of serine/threonine protein kinases that transduce extracellular stimuli into intracellular posttranslational and transcriptional responses. A variety of extracellular stimuli activate intracellular MAPKs by phosphorylation, which modulates the intracellular responses that drive different downstream signaling [6]. It is well established that MAPK activation mechanisms are involved in the modulation of nociceptive information and the peripheral and central sensitization produced by intense noxious stimuli [7–12]. Several studies have demonstrated that MAPK pathways play essential roles in inflammation and tissue remodeling [13, 14], and the inhibition of MAPKs produces anti-inflammatory effects in various inflammatory diseases [13]. MAPKs belong to a highly conserved family of serine/threonine protein kinases and are well known to be involved in various aspects of cell signaling and gene expression in the central nervous system (CNS) [15]. MAPKs are thought to be involved in the modulation of inflammation-induced pain hyperalgesia in
DRGs and the spinal cord [16]. When the physiopathological mechanisms of inflammatory pain have been studied in patients with amputation neuma, spinal cord injury, or other causes of neuropathic pain, the mitogen-activated protein kinases (MAPKs) have been found to play a critical role. The phosphorylated forms of these kinases maintain and increase pain signals from the peripheral nociceptors or DRGs by posttranslationally modifying proteins and regulating the transcription of critical genes.

It is demonstrated that specific members of the MAPK family might mediate pain-associated spatial and temporal plasticity in the HF; for example, the local injection of MAPK inhibitors significantly depresses thermal and mechanical hyperalgesia [10, 17–19]. Following peripheral nerve injury, ERK and p38 MAPK are activated and their expression levels are increased in the spinal dorsal horns [7, 10, 20]. There is also evidence supporting that p38 reduces pain by inhibiting p38 phosphorylation via decreasing TNF-𝛼 [21]. Additionally, JNK signaling plays a crucial role in mediating antinociception and chronic tolerance to the antinociceptive effects of morphine in acute, inflammatory, and neuropathic pain states [22]. The spinal activation mechanisms of MAPK signaling pathways in both neurons and microglia are involved in the antinociceptive effects of pregabaline in a zymosan-induced peripheral inflammatory pain model [23].

Notwithstanding these reports, the underlying role of MAPKs in CCD rats remains unexplored with modern techniques. In the present study, we thus assessed the effects of MAPKs inhibitors in gene and protein expressions and cellular distribution in DRGs and also their effects on allodynia in CCD rats.

2. Materials and Methods

2.1. Animals and Surgical Procedure. Adult male Wistar rats weighing 180–220 g were provided by the Experimental Animal Center of Shandong University and were housed in a pathogen-free room at a temperature of 20 ± 2 ºC at two per cage on a 12 h light/dark cycle with water and food available ad libitum. The animals were allowed 7 days to habituate to the housing prior to manipulation and half an hour to habituate to the experimental environment before every behavioral study was performed. All experimental procedures were approved by the Animal Care and Use Committee of the Shandong University.

Rats were anesthetized by 10% chloral hydrate (300 mg/100 g i.p.), and then two stainless steel rods were implanted unilaterally into the intervertebral foramen at L4 and L5 [24, 25]. Rats in sham-operation group underwent the same operation but with no steel bar insertion. The rats with autophagy phenomenon, feeling deficiency, and disability were eliminated.

2.2. Behavioral Testing. Behavioral testing was performed using the ipsilateral hind paw of the animals prior to the operation, on postoperative day 4, and 2 hours after the injection of inhibitors. The paw withdrawal mechanical thresholds (PWMTs) were evaluated with a BME-404 Mechanical Analgesia Tester (CAMS-Chinese Academy of Medical Sciences, Beijing, China) [25]. The probe was pressed against the lateral plantar surface of the hind paw with sufficient force. A positive response was noted when the paw was immediately withdrawn. The rats were tested again at least five minutes later, the tests were repeated five times, and the average was calculated and used in the statistical analyses.

2.3. Western Blot Analysis. Four days after surgery, CCD rats were intrathecally injected with MAPKs inhibitors for 2 h. The L4 and L5 ganglia from the operated side were quickly and carefully harvested. The samples of total protein were separated by sequential 5% and 10% SDS-PAGE and then transferred to polyvinylidene fluoride membranes. The membranes were incubated in 5% milk for 2 h at room temperature. Next, the membranes were incubated with primary antibody at 4 ºC overnight and subsequently with horseradish peroxidases- (HRP-) conjugated secondary antibodies for 1 h. The signals were detected with Immobilon™ Western Chemiluminescent HRP Substrate. The primary antibodies were rabbit anti-ERK polyclonal antibody (1:1,000, CST, USA), rabbit anti-p-ERK polyclonal antibody (1:2,000, CST, USA), rabbit anti-JNK polyclonal antibody (1:1,000, CST, USA), rabbit anti-p-JNK polyclonal antibody (1:1,000, CST, USA), rabbit anti-p38 polyclonal antibody (1:200, CST, USA), and rabbit anti-P-p38 polyclonal antibody (1:1,000, CST, USA). The second antibody was goat-anti-rabbit antibody (1:8,000, Zhongshan Golden Bridge, Beijing, China). The protein bands were developed with a FluoroChem 9900 imaging system (USA), and the quantifications of the intensities of the bands were performed with the Quantity One software and normalized to β-tubulin (1:1,000, CST, USA).

2.4. Immunolocalization of p38, ERK, and JNK in Dorsal Root Ganglia. Rats were deeply anesthetized with 5% isoflurane and perfused transcardially with cold normal saline followed by fixative containing 4% paraformaldehyde in 0.1 M phosphate-buffered saline (PBS, pH 6.9). The ipsilateral lumbar L4-L5 DRGs were removed rapidly after perfusion, postfixed in the same fixative overnight at 4 ºC, and then dehydrated and paraffin-infused. A series of paraffin sections (4 μm) were cut using a rotary microtome. The sections were incubated separately in mixtures of the following primary antibodies at 4 ºC overnight: rabbit anti-ERK polyclonal antibody (1:200, CST, USA), rabbit anti-JNK polyclonal antibody (1:200, CST, USA), and rabbit anti-p38 polyclonal antibody (1:50, CST, USA). The primary antibodies were incubated with mouse-anti-NF200 polyclonal antibody (1:1,000, Abcam, Cambridge, UK). Then the sections were incubated in Alexa Fluor 488-conjugated AffiniPure Donkey Anti-Rabbit IgG (H+L) and Alexa Fluor 594-conjugated Donkey Anti-Mouse IgG (H+L) for 2 h at room temperature. DAPI was used to stain the cell nuclei.

Labeled sections were examined under an Olympus-u-rfl-t/dp 72 automatic fluorescence microscope using the image analysis system of the microscope (JA) and analyzed using the IPP.6 software. For the quantitative analyses of
the numbers of positive neurons, three immunofluorescent stained nonconsecutive sections were imaged per ganglion. The data were collected from three animals for each inhibitor (SB203580, U0126, and SP600125).

2.5. Real-Time Quantitative RT-PCR. L4 and L5 ganglia were harvested in the same manner as described above. Fragments of p38, JNK, ERK, or β-actin were amplified with the following primers: p38 (forward, 5'-CCTGGGAGGGCT- GAAGTA-3'; reverse, 5'-ACGGACCAATATCCACCTG-TCT-3'), JNK (forward, 5'-AGCCTTTGCCCTGGTGTC-3'; reverse, 5'-AAATGGTCAACAGAGCC-3'), ERK1 (forward, 5'-CCAGACTGCTATCAAGAAG-3'; reverse, 5'- TCCATGAGGTCTGAACAA-3'), ERK2 (forward, 5'- TGCCGTAAGCTAGTTGT-3'; reverse, 5'-TGGGCTCAT- CACTGGGT-3'), and β-actin (forward, 5'-AGACCTTCA- ACACCCGAG-3'; reverse, 5'-CACGATTTCCCTCTCACG- 3'). Instrument control, automated data collection, and data analysis were all performed using the Light Cycler software program, version 4.0. The 2^ΔΔCT method was used to analyze the data.

2.6. Chemicals and Reagents. The following chemicals were used in this study: SB203580 (p38 inhibitor, CST, USA, recommended concentration = 40 μmol/L), SP600125 (JNK inhibitor, CST, USA, recommended concentration = 50 μmol/L), and U0126 (ERK inhibitor, CST, USA, recommended concentration = 40 μmol/L). All of the chemicals were dissolved in DMSO, and the final experimental dilutions were made in normal saline on the day of the experiment.

2.7. Data Analysis and Statistics. All calculations and statistical analyses were performed using Prism 5.0 (Graph Pad Software, San Diego, CA, USA). A two-way repeated measures ANOVA was used to analyze the differences in the PWLs, the level of protein and gene expression, and the neurons distribution. Values in the test were expressed as means ± SDs. P values < 0.05 were considered significant.

3. Results

3.1. PWMT Changes after the CCD Operation. To detect whether the inhibitors of MAPKs attenuated CCD-induced neuropathic pain, PWMTs were examined before surgery, 4 days after surgery, and 2 h after inhibitors administration. As shown in Figure 1, the CCD group developed evident mechanical allodynia hyperalgesia in the ipsilateral hind paw compared with the control group. The PWMT significantly decreased at 4 days after the CCD operation (n = 8 in each group; **P < 0.01). Furthermore, CCD-induced allodynia was attenuated by SB203580, SP600125, and U0126 (n = 8 in each group; *P < 0.05), while there was no significant difference between sham group and control group (n = 8 in each group).

3.2. Changes in Protein Expressions of p38, ERK, and JNK in the DRGs. To investigate whether p38, ERK, and JNK expression and phosphorylation were altered, pharmacological inhibitors were administered to the CCD rats. As demonstrated in Figure 2, the levels of p38, JNK, ERK, P-p38, P-JNK, and P-ERK protein expression in the CCD rats significantly increased (n = 5, *P < 0.05, and **P < 0.01 compared with control group; *P < 0.05 and **P < 0.01 compared with sham group). These CCD-induced increases in protein expression level were diminished significantly by inhibitors (SB203580, SP600125, and U0126) administration (*P < 0.05 and ##P < 0.01 compared with CCD groups).

3.3. Changes in Gene Expressions of p38, ERK, and JNK in the DRGs. Pharmacological inhibitors of MAPKs not only diminished the protein expression of p38, ERK, and JNK in DRGs of CCD rats but also affected the level of gene expressions. As demonstrated in Figure 3, the levels of p38, JNK, and ERK gene expression in the CCD rats significantly increased (n = 6 and *P < 0.05 and **P < 0.01 compared with control group). These CCD-induced increases in gene expression level were diminished significantly by inhibitors (SB203580, SP600125, and U0126) administration (*P < 0.05 and ##P < 0.01 compared with CCD groups).

3.4. Changes in p38, ERK, and JNK Distributions in DRG Neurons. To quantify the proportions of positive cells within defined subsets of sensory neurons, we counted the numbers of positive neurons detected in the NF200-immunoreactive neuronal profiles.

As demonstrated in Figures 4(a)–4(c), p38, JNK, and ERK were expressed in both the nuclei and cytoplasm; the proportions of NF200 positive large size neurons among all of the neurons in the DRG tissues increased significantly (n = 6 and *P < 0.05 and **P < 0.01) after CCD surgery compared with control groups. After SB203580, SP600125, or U0126 administration, the proportions of NF200 positive neurons significantly decreased (n = 6 and *P < 0.05 and...
**Figure 2**: Effects of the inhibitors on protein expressions of p38, JNK, and ERK and their phosphorylation. (a)–(c) show the expressions of p38, P-p38, JNK, P-JNK, ERK, and P-ERK after SB203580, U0126, and SP600125 administration, and (d)–(f) show the iods compared with β-tubulin. *P < 0.05, **P < 0.01, and n = 5 for each group compared with the control group; #P < 0.05 and ##P < 0.01 compared with the sham group; n = 5 in each group; &P < 0.05 and &&P < 0.01 compared with the CCD group; n = 5 in each group.

**4. Discussion**

This is the first study showing the role of MAPK pathways in neuropathic pain in DRGs of CCD rats. Intrathecal administration of the MAPKs inhibitors, SB203580,
SP600125, and U0126, resulted in a partial reduction in CCD-induced mechanical allodynia. The reduction of allodynia was associated with significant depression in the level of both MAPKs gene and protein expression in CCD rats, and the large size MAPKs positive neurons in dorsal root ganglia were crucial in maintaining the neuropathic pain.

The CCD model has been proven to be a typical model of neuropathic pain. In CCD rats, the direct mechanical compression of the DRG [26] and secondary inflammatory processes [27] induce hyperexcitability of the DRG neurons, and this hyperexcitability is associated with allodynia and changes in the lower paw withdrawal latency after CCD surgery. Using specific inhibitors of MAPKs contributed to the attenuation of mechanical allodynia in CCD rats. MAPK pathways may be new targets of neuropathic pain treatment.

In the CNS, the activation of the p38 MAPK pathway constitutes a key step in the development of neuroinflammation. Inflammatory stimuli bind to receptors on the cell surface to trigger intracellular signal transduction pathways, such as the p38 MAPK pathways [28, 29]. Subsequently, intracellular p38 MAPK is activated and profoundly modulates somatic inflammatory responses. The expression of ERK in the DRGs has been implicated in the induction of neuropathic pain behaviors in rat models of chronic constriction injury (CCI) and the normalization of those behaviors after decompression of the CCI reflects the reversal of the pain behaviors [30]. The expression of JNK is also activated in the spinal DRG after nerve injury, and this expression of p-JNK can maintain mechanical allodynia [31]. Inhibitors of MAPKs administration in recommendatory dose and time specifically decreased the upregulated protein expression of MAPKs (p38 and P-p38 by SB203580, JNK and P-JNK by SP600125, and ERK and P-ERK by U0126) in CCD rats. Similar changes were found in the gene expression of p38, JNK, and ERK. However, the dose/time dependence of these inhibitors may require further analysis.

Neurons in DRGs are divided into three types (large: >35 μm with Aβ fiber; middle: 20–35 μm with Aδ fiber; small: <20 μm with C fiber), mainly depending on their size, electrophysiological property, and neuronal processes [32]; generally, Aβ fiber conducts proprioception and tactile sense, C fiber conducts nociception signal, and Aδ fiber conducts both. The proportions of NF200 positive large size neurons among the p38, JNK, or ERK positive neurons in the DRG tissues increased significantly after CCD surgery; then the proportions were decreased by SB203580, SP600125, or U0126 administration, while the proportions of NF200 negative small size neurons change without explicable regulation. Therefore, the large size neurons with Aβ fiber contributed mainly to the MAPKs mediated neuropathic pain in CCD rats.

5. Conclusions

In conclusion, the present study demonstrated that specific inhibitors of MAPKs contributed to the attenuation of mechanical allodynia in CCD rats and the large size MAPKs positive neurons in dorsal root ganglia were crucial. Therefore, MAPK pathways are involved in the mechanism of neuropathic pain in CCD rats.

Competing Interests

The authors declare no conflict of interests.

Authors’ Contributions

Yu-Juan Qu and Shou-Wei Yue conceived and designed the experiments. Yu-Juan Qu, Lei Jia, and Xiao Zhang performed the experiments. Yu-Juan Qu and Lei Jia analyzed the data. Yu-Juan Qu, Xiao Zhang, and Hui Wei interpreted the results. Yu-Juan Qu and Shou-Wei Yue wrote the paper.
Figure 4: Continued.
Figure 4: Changes in the distributions of p38, JNK, or ERK/NF200 positive or negative neurons in the DRG tissue. (a)–(c) illustrate the neuronal distributions and ratios of the NF200 positive or negative neurons. $N = 6$; $^{*}P < 0.05$ and $^{**}P < 0.01$ compared with the control group; $^{*}P < 0.05$ and $^{**}P < 0.01$ compared with the CCD group and $^{**}P < 0.01$ compared with the control group. Scale bars: 100 $\mu$m for the low-power field and 20 $\mu$m for high-power field (→: NF200 positive neurons).

Acknowledgments
This study was supported by National Natural Science Foundation of China (Grant no. 81372123). All animal experiments were performed at the Animal Care Center of the Key Laboratory of Cardiovascular Remodeling and Functional Research of Shandong University (Jinan, Shandong, China).

References
[1] K. Hargreaves, R. Dubner, F. Brown, C. Flores, and J. Joris, “A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia,” Pain, vol. 32, no. 1, pp. 77–88, 1988.
[2] I. Tegeder, E. Niederberger, R. Schmidt et al., “Specific inhibition of I$\kappa$B kinase reduces hyperalgesia in inflammatory and neuropathic pain models in rats,” The Journal of Neuroscience, vol. 24, no. 7, pp. 1637–1645, 2004.
[3] M. Gangadhar, R. K. Mishra, D. Sriram, and P. Yogeeshwari, “Future directions in the treatment of neuropathic pain: a review on various therapeutic targets,” CNS and Neurological Disorders—Drug Targets, vol. 13, no. 1, pp. 63–81, 2014.
[4] F. V. Hassani, R. Rezaee, H. Szegara, M. Hashemzaei, K. Shirani, and G. Karimi, “Effects of silymarin on neuropathic pain and formalin-induced nociception in mice,” Iranian Journal of Basic Medical Sciences, vol. 18, no. 7, pp. 715–720, 2015.
[5] W. S. Kingery, “A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes,” Pain, vol. 73, no. 2, pp. 123–139, 1997.
[6] A. G. Turjanski, J. P. Vaqué, and J. S. Gutkind, “MAP kinases and the control of nuclear events,” Oncogene, vol. 26, no. 22, pp. 3240–3253, 2007.
[7] R.-R. Ji, H. Baba, G. J. Brenner, and C. J. Woolf, “Nociceptive-specific activation of ERK in spinal neurons contributes to pain hypersensitivity,” Nature Neuroscience, vol. 2, no. 12, pp. 1114–1119, 1999.
[8] S.-X. Jin, Z.-Y. Zhuang, C. J. Woolf, and R.-R. Ji, “p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain,” The Journal of Neuroscience, vol. 23, no. 10, pp. 4017–4022, 2003.
[9] Y. Kawasaki, T. Kohno, Z.-Y. Zhuang et al., “Ionotropic and metabotropic receptors, protein kinase A, protein kinase C, and Src contribute to C-fiber-induced ERK activation and cAMP response element-binding protein phosphorylation in dorsal horn neurons, leading to central sensitization,” The Journal of Neuroscience, vol. 24, no. 38, pp. 8310–8321, 2004.
[10] K. Obata and K. Noguchi, “MAPK activation in nociceptive neurons and pain hypersensitivity,” Life Sciences, vol. 74, no. 21, pp. 2643–2653, 2004.
[11] X.-S. Song, J.-L. Cao, Y.-B. Xu, J.-H. He, L.-C. Zhang, and Y.-M. Zeng, "Activation of ERK/CREB pathway in spinal cord contributes to chronic constrictive injury-induced neuropathic pain in rats," *Acta Pharmacologica Sinica*, vol. 26, no. 7, pp. 789–798, 2005.

[12] R.-R. Ji, R. W. T. Gereau, M. Malcangio, and G. R. Strichartz, "MAP kinase and pain," *Brain Research Reviews*, vol. 60, no. 1, pp. 135–148, 2009.

[13] K. Newton and V. M. Dixit, "Signaling in innate immunity and inflammation," *Cold Spring Harbor Perspectives in Biology*, vol. 4, no. 3, 2012.

[14] S. Khan, O. Shehzad, H.-G. Jin et al., "Anti-inflammatory mechanism of 15,16-epoxy-3β,4-no.3,2012.

[15] M. Koistinaho and J. Koistinaho, "Role of p38 and p44/42 mitogen-activated protein kinases in microglia," *Glia*, vol. 40, no. 2, pp. 175–183, 2002.

[16] R.-R. Ji, K. Beffort, G. J. Brenner, and C. J. Woolf, "ERK MAP kinase activation in superficial spinal cord neurons induces prodynorphin and NK-1 upregulation and contributes to persistent inflammatory pain hypersensitivity," *The Journal of Neuroscience*, vol. 22, no. 2, pp. 478–485, 2002.

[17] M.-G. Liu, R.-R. Wang, X.-F. Chen, X.-Y. Cui, and J. Chen, "Differential roles of ERK, JNK and p38 MAPK in pain-related spatial and temporal enhancement of synaptic responses in the hippocampal formation of rats: multi-electrode array recordings," *Brain Research*, vol. 1382, pp. 57–69, 2011.

[18] D. C. Choi, J. Y. Lee, E. J. Lim, H. H. Baik, T. H. Oh, and T. Y. Yune, "Inhibition of ROS-induced p38MAPK and ERK activation in microglia by acupuncture relieves neuropathic pain after spinal cord injury in rats," *Experimental Neurology*, vol. 236, no. 2, pp. 268–282, 2012.

[19] J. A. Black, L. Nikolajsen, K. Kroner, T. S. Jensen, and S. G. Waxman, "Multiple sodium channel isoforms and mitogen-activated protein kinases are present in painful human neurons," *Annals of Neurology*, vol. 64, no. 6, pp. 644–653, 2008.

[20] L. D. Cesare Mannelli, C. Gherardini, A. Toscano, A. Pacini, and A. Bartolini, "The neuropathy-protective agent acetyl-l-carnitine activates protein kinase C-γ and MAPKs in a rat model of neuropathic pain," *Neuroscience*, vol. 165, no. 4, pp. 1345–1352, 2010.

[21] C. K. F. Lima, R. M. Silva, R. B. Lacerda et al., "LASSBio-1135: a dual TRPV1 antagonist and anti-TNF-alpha compound orally effective in models of inflammatory and neuropathic pain," *PLoS ONE*, vol. 9, no. 6, Article ID e99510, 2014.

[22] D. J. Marcus, M. Zee, A. Hughes et al., "Tolerance to the antinociceptive effects of chronic morphine requires c-Jun N-terminal kinase," *Molecular Pain*, vol. 11, no. 1, article 34, 2015.

[23] C. J. Young, P. Kihyun, and B. K. Young, "Inhibition of mitogen-activated protein kinases phosphorylation plays an important role in the anti-nociceptive effect of pregabalin in zymosan-induced inflammatory pain model," *Biological and Pharmaceutical Bulletin*, vol. 37, no. 10, pp. 1694–1698, 2014.

[24] X.-L. Ding, Y.-H. Wang, L.-P. Ning et al., "Involvement of TRPV4-NO-cGMP-PKG pathways in the development of thermal hyperalgesia following chronic compression of the dorsal root ganglion in rats," *Behavioural Brain Research*, vol. 208, no. 1, pp. 194–201, 2010.